Associated Papers
Clinical characteristics and whole exome sequencing in JAK2V617F- and CALR-unmutated essential thrombocythemia.
Thammayot S et al.
Hematology (amsterdam, Netherlands), 2026
Clonal Hematopoiesis of Indeterminate Potential and Clonal Cytopenias of Undetermined Significance: 2026 Update on Clinical Associations and Management Recommendations.
Mangaonkar AA et al.
American Journal of Hematology, 2026
Mutant SRSF2-associated impaired erythropoiesis is defined by increased mTORC1 signaling due to FYN missplicing.
Jutzi JS et al.
Leukemia, 2026
Protocol for generating megakaryocytes from patient induced pluripotent stem cells for disease modeling and compound screening.
Chawla P et al.
Star Protocols, 2026
Risk stratification of patients with TP53-mutated myeloproliferative neoplasms.
Rolles B et al.
Leukemia, 2026
Clinical relevance of mosaic variants detected by exome sequencing.
Ghosh R et al.
The Journal of Allergy and Clinical Immunology, 2026
A Real-Time, Programmable, and Multiplex Ligation Chain Reaction-MNAzyme Platform for Single-Nucleotide Variant Detection.
Zhang J et al.
Analytical Chemistry, 2026
Inhibition of the EBF1-ITGB8 Axis in Bone Marrow Niche Ameliorates Hallmarks of Myelofibrosis.
Tsurkan L et al.
Biorxiv : the Preprint Server for Biology, 2026
Thrombo-inflammatory endothelial signatures in JAK2 -mutated myeloproliferative neoplasms.
Abosabie SAS et al.
Biorxiv : the Preprint Server for Biology, 2026
The Role and Impact of Non-driver Gene Mutations in Myelofibrosis.
Boldrini V et al.
Current Hematologic Malignancy Reports, 2026
JAK2 pathogenic variants in ischemic stroke: low prevalence and pre-screening model.
Zhao J et al.
Journal of Neurology, 2026
Maladaptive somatic gene rescue as predisposition to JAK2 molecular abnormalities? Insights from an Israeli family.
Borsani O et al.
Annals of Hematology, 2026
Targeted deep sequencing identifies mosaicism in patients with immune dysregulation.
Schmitz EG et al.
The Journal of Allergy and Clinical Immunology, 2026
BESTish: A Diffusion-Approximation Framework for Inferring Selection and Mutation in Clonal Hematopoiesis.
Wang RY et al.
Biorxiv : the Preprint Server for Biology, 2026
B-cell acute lymphoblastic leukemia following myelodysplastic syndromes: a case report and literature review.
Ding H et al.
Journal of Hematopathology, 2026
JAK2V617F reprograms Hypoxia Inducible Factor-1 to induce a non-canonical hypoxia regulon in myeloproliferative neoplasms.
Kealy D et al.
Leukemia, 2026
Strategies for identifying NUP98 rearrangements in adult myeloid neoplasms.
Yuen LD et al.
Haematologica, 2026
CHIP ahoy: charting a decade of discovery in clonal hematopoiesis.
Wong CK et al.
Haematologica, 2026
High Frequency of Germline ATM Variants in Familial Philadelphia-Negative Myeloproliferative Neoplasms.
Ramundo F et al.
American Journal of Hematology, 2026
JAK2 V617F Mutation Screening for Peripheral Arterial Thrombosis.
Villa A et al.
Seminars in Thrombosis and Hemostasis, 2026
Sabotaged Integral HSC Heterogeneity Underlies Essential Thrombocythemia Development.
Tong J et al.
Advanced Science (weinheim, Baden-wurttemberg, Germany), 2026
Targeting DESI2 as a Novel Therapeutic Strategy for JAK2-Mutant Leukemias.
Mei H et al.
Advanced Science (weinheim, Baden-wurttemberg, Germany), 2026
A Novel, Ruxolitinib-Sensitive, CCDC6::JAK2 Fusion Gene in a Patient With Atypical, JAK2 Unmutated, Polycythemia Vera-Like, Myeloproliferative Neoplasm.
Bartalucci N et al.
American Journal of Hematology, 2026
Targeting DDX5 using FL118 suppresses mTOR signaling and tumorigenicity in JAK2V617F-driven myeloproliferative neoplasms.
Takeda K et al.
International Immunopharmacology, 2026
2025 report on advances in thoracic aortic disease research.
Wu J
Journal of Thoracic Disease, 2026
Copy-Neutral Loss of Heterzygosity in Myelofibrosis: Parallel Evaluation with Optical Genome Mapping and Single-Nucleotide Polymorphism Arrays.
Díaz-González Á et al.
The Journal of Molecular Diagnostics : Jmd, 2026
Primary Indolent Acute Promyelocytic Leukemia.
Wolfenbarger B et al.
Hematology Reports, 2026
Ultra-Sensitive Mutation Detection Technology in Myeloid Neoplasms: New Tools for Patient Monitoring.
Ferrando A et al.
Journal of Clinical Medicine, 2026
Diagnostic reassessment in myeloproliferative neoplasms: the value of functional iron parameters and JAK2 allelic burden.
González-Resina R et al.
Annals of Hematology, 2026
Systematic functional dissection of germline noncoding risk variants impacting clonal hematopoiesis.
Nguyen T et al.
Biorxiv : the Preprint Server for Biology, 2026
Immunomodulatory role of megakaryocytes in the hematopoietic niche of myeloproliferative neoplasms.
Yang X et al.
Haematologica, 2026
A framework for the molecular identification of CHIP for clinical research.
Harraka P et al.
Hgg Advances, 2026
Loss of FBXO11 establishes a stem cell program in acute myeloid leukemia by dysregulating LONP1.
Kincross H et al.
The Journal of Clinical Investigation, 2026
FBXO11 suppression rewires an NPM1-centered interactome influencing the progression of myelodysplastic syndrome.
Niederkorn M et al.
The Journal of Clinical Investigation, 2026
Heritability and Transcriptional Impact of JAK3, STAT5A and STAT6 Variants in a Tyrolean Family.
Lee HK et al.
International Journal of Molecular Sciences, 2026
Allosteric inhibition of JAK2 with lysine-reactive compounds that bind the pseudokinase domain.
Primi MC et al.
European Journal of Medicinal Chemistry, 2026
Expanding the clinical tumor phenotype of the EPAS1-asssociated tumor syndrome.
Cole Y et al.
The Journal of Clinical Endocrinology and Metabolism, 2026
Inflammageing and clonal haematopoiesis interplay and their impact on human disease.
Hajishengallis G et al.
Nature Reviews. Molecular Cell Biology, 2026
Triple-negative primary myelofibrosis: a comparative analysis of phenotype, genotype, and outcome.
Bashir YA et al.
Blood Cancer Journal, 2026
Whole-Genome Landscape of Retinal Hemangioblastomas.
Bals K et al.
Translational Vision Science & Technology, 2026
Genetic Susceptibility to Adult Cerebral Venous Thrombosis: An Updated Meta-Analysis of Candidate Gene Studies.
Han G et al.
Stroke, 2026
Atypical presentation and association of medullary thyroid carcinoma: reports from a tertiary care center in Northwest India.
Chakraborty AM et al.
Endocrinology, Diabetes & Metabolism Case Reports, 2026
Impact of Molecular Evaluations in the Biology, Diagnosis, and Prognostication of Patients With Mastocytosis.
Hoermann G et al.
The Journal of Allergy and Clinical Immunology. in Practice, 2026
Clonal Progression and Leukemic Transformation of a TP53 Mutated Post-Polycythaemia Vera Myelofibrosis.
Minović I et al.
European Journal of Haematology, 2026
KIT-Targeting Drugs in the Management of Nonadvanced and Advanced Systemic Mastocytosis.
Reiter A et al.
The Journal of Allergy and Clinical Immunology. in Practice, 2026